Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
1. TYRA receives FDA clearance for TYRA-300's Phase 2 trial in NMIBC. 2. Dr. Goluboff appointed as SVP, enhancing clinical development expertise. 3. TYRA-300 targets FGFR3 mutations, prevalent in 60-80% of IR NMIBC cases. 4. First patient expected to be dosed in SURF302 by Q2 2025. 5. Immediate CR data anticipated within three months of dosing initiation.